Patents by Inventor Linda Perry Briley

Linda Perry Briley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer
    Patent number: 10004742
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Parham, Charles J. Cox, Colin F. Spraggs
  • Method of Treating Cancer
    Publication number: 20170065590
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Parham, Charles J. Cox, Colin F. Spraggs
  • Method of treating cancer
    Patent number: 9539257
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 10, 2017
    Assignee: Novartis AG
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs
  • METHOD OF TREATING CANCER
    Publication number: 20150231137
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: February 27, 2015
    Publication date: August 20, 2015
    Inventors: Nan BING, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs
  • METHOD OF TREATING CANCER
    Publication number: 20120156200
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 21, 2012
    Applicant: SMITHKLINE BEECHAM (CORK) LTD.
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs